The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032

The Business Research Company’s clinical oncology next-generation sequencing market report forecasts the clinical oncology next-generation sequencing market size to grow to $0.75 Billion by 2027, with a CAGR (compound annual growth rate) of more than 13%.

Learn More On The Clinical Oncology Next Generation Sequencing Market Report 2023 – https://www.thebusinessresearchcompany.com/report/clinical-oncology-next-generation-sequencing-global-market-report

Clinical Oncology Next Generation Sequencing Market Size Forecast
The global clinical oncology next-generation sequencing market is expected to grow from $0.39 billion in 2022 to $0.45 billion in 2023 at a compound annual growth rate (CAGR) of 14.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The clinical oncology next generation sequencing market is expected to grow from $0.75 billion in 2027 at a CAGR of 13.7%.

North America held the largest clinical oncology next-generation sequencing market share.

Key Clinical Oncology Next Generation Sequencing Market Driver ­– Rise In The Number Of Cancer Cases Across The Globe
According to the American Cancer Society, there were 1.9 million new cases and 0.6 million cancer deaths in 2021 in the USA. The four most common types of cancer worldwide are lung, prostate, bowel, and female breast cancer, accounting for 43% of all the new cancer cases. Therefore, the rise in cancer incidence rate globally is anticipated to boost the demand for the clinical oncology next-generation sequencing market.

Request for A Sample Of The Global Clinical Oncology Next Generation Sequencing Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3344&type=smp

Key Clinical Oncology Next Generation Sequencing Market Trend – Increasingly Investing In Automation Of Workflow
Companies in the clinical oncology next-generation sequencing are increasingly investing in automation of workflow to increase precision and reduce the sample-to-sample variability. For instance, Agilent automation solutions have developed an automation system that allows increasing the number of reactions that can perform in parallel, reducing the amount of sample processing time, and increasing the number of samples which can be processed while reducing the variability amount from sample to sample. Companies such as Sophia Genetics are also investing in data-driven medicine that looks into automating DNA sequencing to better diagnose and treat patients.

Clinical Oncology Next Generation Sequencing Market Segment
1) By Technology: Ion Semiconductor Sequencing, Pyro-Sequencing, Synthesis Sequencing, Real Time Sequencing, Ligation Sequencing, Reversible Dye Termination Sequencing, Nano-Pore Sequencing
2) By Application: Screening, Companion Diagnostics, Other Diagnostics
3) By End User: Hospital Laboratories, Clinical Research Organizations, Diagnostic laboratories

Clinical Oncology Next Generation Sequencing Market Major Players and Strategies
Major players in the clinical oncology next-generation sequencing market are Thermo Fisher Scientific (Qiagen), Oxford Nanopore Technologies, QIAGEN, Myriad Genetics, Illumina, F. Hoffmann-La Roche, Perkin Elmer, Agilent Technologies, Pacific Bioscience, and Caris Life Sciences.

In April 2021, Agilent Technologies, a US-based life sciences technology company, acquired Resolution Bioscience for an undisclosed amount. The acquisition would expand Agilent’s capabilities in the fields of next-generation sequencing for cancer diagnostics. Resolution Bioscience is a US-based developer of next-generation sequencing (NGS)-based precision oncology solutions.

The Clinical Oncology Next Generation Sequencing Global Market Report 2023 covers regional data on clinical oncology next-generation sequencing market size, clinical oncology next-generation sequencing market trends and drivers, opportunities, strategies, and clinical oncology next-generation sequencing market competitor analysis. The countries covered in the clinical oncology next-generation sequencing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA, and the major seven regions are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

Next generation sequencing (NGS) is a process used to determine the sequence of nucleotides in a section of DNA and is used in oncology research. NGS is used to identify rare cancer mutations and familial cancer mutation carriers and to provide molecular rationale for appropriate targeted therapy.

View More Reports Related To The Clinical Oncology Next Generation Sequencing Market –
Oncology Molecular Diagnostics Global Market Report 2023
Cancer Diagnostics Global Market Report 2023
Cancer Vaccines Global Market Report 2023

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: